Cory Edwards, MD
Neurology · Grand Forks, NDNPI 1770876815
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AstraZeneca at 36.0% of the total. Reporting peaked in 2024 at $287 and has fallen 50.4% since, to $142 in 2025. That places this record below the midpoint for neurology clinicians in ND, where the typical reported total is $432.
Across 13 payments — averaging $40.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$188
- UCB, Inc.$94
- Eisai Inc.$81
- Springworks Therapeutics, Inc.$77
- Novo Nordisk$42
- Lilly USA, LLC$15
- plus $26 from 2 others
What the payments were for
- Food & beverage$523100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 3 | $188 |
| UCB, Inc. | 2 | $94 |
| Eisai Inc. | 2 | $81 |
| Springworks Therapeutics, Inc. | 1 | $77 |
| Novo Nordisk | 2 | $42 |
| Lilly USA, LLC | 1 | $15 |
| AbbVie | 1 | $14 |
| Merz North America, Inc. | 1 | $12 |
How this compares
$523 in reported general payments places this provider in the 50th percentile of 39 neurology providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 17 | $117,737 |
| Kesimpta PenOfatumumab | 13 | $113,566 |
| Nurtec OdtRimegepant Sulfate | 15 | $31,678 |
| EpidiolexCannabidiol (Cbd) | 16 | $24,084 |
| Emgality PenGalcanezumab-Gnlm | 31 | $21,615 |
| Lacosamide | 59 | $12,253 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 263 | $10,864 |
| Ajovy SyringeFremanezumab-Vfrm | 12 | $8,205 |
| Felbamate | 15 | $7,073 |
| Memantine Hcl | 123 | $5,100 |
| Pregabalin | 172 | $3,501 |
| Pyridostigmine Bromide | 35 | $3,448 |
| Levetiracetam | 135 | $3,073 |
| Propranolol Hcl ErPropranolol Hcl | 41 | $2,281 |
| Gabapentin | 83 | $2,158 |
Paid to pharmacies, not to this prescriber.
Other neurology in Grand Forks
- James MilesGrand Forks$3K
- Rebecca NovacekGrand Forks$554
- Matthew RollerGrand Forks$345
- Tanya HarlowFargo$73K
- Susan ScarberryFargo$67K
- Sarah KendroudFargo$42K
- Scott BellistonFargo$9K
- Jess MillerBismarck$2K
- Gary MillerFargo$2K
- Ralph DunniganBismarck$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.